Biostage, Inc. (BSTG)
| Market Cap | 11.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -3.74M |
| Shares Out | 9.39M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $1.25 |
| Previous Close | $1.21 |
| Change ($) | 0.04 |
| Change (%) | 3.31% |
| Day's Open | 1.21 |
| Day's Range | 1.21 - 1.25 |
| Day's Volume | 1,395 |
| 52-Week Range | 0.80 - 3.06 |
HOLLISTON, Mass., May 24, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its novel Cellfra...
HOLLISTON, Mass., April 13, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing next-generation bioengineered esophageal implants, today a...
About BSTG
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is head... [Read more...]
| Industry Biotechnology | Founded 2007 |
| Stock Exchange OTCMKTS | Ticker Symbol BSTG |